HRP20150510T1 - Äśestice mezenhimskih matiäśnih stanica - Google Patents
Äśestice mezenhimskih matiäśnih stanica Download PDFInfo
- Publication number
- HRP20150510T1 HRP20150510T1 HRP20150510TT HRP20150510T HRP20150510T1 HR P20150510 T1 HRP20150510 T1 HR P20150510T1 HR P20150510T T HRP20150510T T HR P20150510TT HR P20150510 T HRP20150510 T HR P20150510T HR P20150510 T1 HRP20150510 T1 HR P20150510T1
- Authority
- HR
- Croatia
- Prior art keywords
- exosome
- disease
- mesenchymal stem
- kda
- complexes
- Prior art date
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims 8
- 239000002245 particle Substances 0.000 title 1
- 210000001808 exosome Anatomy 0.000 claims 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 229920000858 Cyclodextrin Polymers 0.000 claims 3
- 230000004071 biological effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 239000003599 detergent Substances 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010059313 Anogenital warts Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 101150082674 E2 gene Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 101150052863 THY1 gene Proteins 0.000 claims 1
- 229920004890 Triton X-100 Polymers 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 241000934136 Verruca Species 0.000 claims 1
- 208000000260 Warts Diseases 0.000 claims 1
- 238000002835 absorbance Methods 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 101150010487 are gene Proteins 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000015322 bone marrow disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000005961 cardioprotection Effects 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 1
- 229930183167 cerebroside Natural products 0.000 claims 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000016532 chronic granulomatous disease Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000002296 dynamic light scattering Methods 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 238000001493 electron microscopy Methods 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 238000010172 mouse model Methods 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 1
- 238000013310 pig model Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 238000001542 size-exclusion chromatography Methods 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 230000007838 tissue remodeling Effects 0.000 claims 1
- 230000001960 triggered effect Effects 0.000 claims 1
- 230000036269 ulceration Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
Claims (14)
1. Egzosom izoliran iz mezenhimske matične stanice i s veličinom između 50-100 nm, potvrđenu elektronskom mikroskopijom, s time da egzosom sadrži najmanje jedno biološko svojstvo mezenhimske matične stanice kao što je kod biološke aktivnosti u kontroliranom mediju mezenhimkih matičnih stanica (KM-MMS).
2. Egzosom u skladu sa zahtjevom 1, pri čemu biološka aktivnost sadrži kardioprotekciju.
3. Egzosom u skladu sa zahtjevom 1 ili 2, koji može reducirati veličinu infarkta kao što je primjerice ispitano na mišjem ili svinjskom modelu miokardijalne ishemije ili reperfuzijske ozljede, ili koji može reducirati oksidativni stres kao što je primjerice ispitano in vitro analizom vodikovim peroksidom(H2O2) kod inducirane stanične smrti.
4. Egzosom u skladu s bilo kojim od prethodnih zahtjeva, pri čemu egzosom sadrži najmanje 70% proteina iz kontroliranog medija mezenhimskih matičnih stanica (KM-MMS), kao što su izabrani iz tablice D1 ili E2, ili su genski produkti gena prikazanih na tablici D2, ili sadrže jedan ili više miRNA kao što je prikazano na tablici E3.
5. Egzosom u skladu s bilo kojim od prethodnih zahtjeva, pri čemu se egzosom sastoji od:
a) Kompleksa molekulske mase >100 kDa, primjerice sadržavajući proteine <100 kDa;
b) Kompleksa molekulske mase >300 kDa, primjerice sadržavajući proteine <300 kDa;ili
c) Kompleksa molekulske mase >1000 kDa.
6. Egzosom u skladu s bilo kojim od prethodnih zahtjeva, pri čemu je egzosom veličine između 50 i 100 nm, određeno filtracijom s 0,2 µM filtrom i koncentracijom s membranom granične molekulske mase do 10 kDa, ili hidrodinamičkim radijusom ispod 100nm, kao što je između 30 i 70 nm, 40 i 60 nm, 45 i 55 nm ili oko 50 nm, kao što je određeno primjerice laserskom difrakcijom ili dinamičkim raspršivanjem svjetla.
7. Egzosom u skladu s bilo kojim od prethodnih zahtjeva, pri čemu egzosom sadži lipid izabran iz skupine koja se sastoji od: fosfolipida, fosfatidil serina, fosfatidil inozitola, fosfatidil kolina, sfingomijelina, ceramida, glikolipida, cerebrozida, steroida, kolesterola, pri čemu je primjerice odnos kolesterola i fosfolipida veći od 0,3-0,4(mol/mol).
8. Egzosom u skladu s bilo kojim od prethodnih zahtjeva, pri čemu egzosom sadrži lipidni raft, ili pri čemu je egzosom netopljiv u neionskom detergentu, posebice Triton-X100, ili pri čemu je egzosom takav da proteini molekulskih masa definiranih zahtjevom 4 većinski ostanu unutar kompleksa molekulskih masa definiranih tim zahtjevima kada je tretiran s neionskim detergentom, ili je egzosom osjetljiv na ciklodekstrin, poželjno 20 mM ciklodekstrin, tako da tretiranje ciklodekstrinom uzrokuje značajno razdvajanje kompleksa definiranih u zahtjevu 5.
9. Egzosom u skladu s bilo kojim od prethodnih zahtjeva, pri čemu egzosom sadrži ribonukleinsku kiselinu(RNA), pri čemu je poželjno da egzosom ima apsorbanciju u vrijednosti od 1.9 (260:280 nm), ili pri čemu egzosom sadrži površinski antigen izabran iz skupine koja se sastoji od: CD9, CD109 and thy-1.
10. Metoda proizvodnje egzosoma prema bilo kojem od prethodnih zahtjeva, koja sadrži:
a) Dobivanje kontroliranog medija mezenhimskih matičnih stanica (KM-MMS);
b) Koncentriranje kontroliranog medija mezenhimskih matičnih stanica;
c) Stavljanje koncentriranog kontroliranog medija mezenhimskih matičnih stanica na kromatografiju isključenjem prema veličini;
d) Odabir frakcija koje apsorbiraju UV zrake.
11. Farmaceutski pripravak koji sadrži egzosom u skladu s bilo kojim od zahtjeva 1-9 i farmaceutski prihvatljiv ekscipijens, otapalo ili nosač.
12. Egzosom u skladu s bilo kojim od zahtjeva 1-9 ili farmaceutski pripravak u skladu sa zahtjevom 11 za uporabu u metodi za liječenje bolesti.
13. Uporaba egzosoma prema bilo kojem od zahtjeva 1-9 za pripremu farmaceutskog pripravka za liječenje bolesti, pri čemu je bolest izabrana iz skupine koja se sastoji od: srčanog zatajenja, bolesti koštane srži, kožnih bolesti, opeklina i degenerativnih bolesti kao što su dijabetes, Alzheimerova bolest, Parkinsonova bolest, rak, miokardijalni infarkt, kutana ozljeda, dermatološki poremećaj, dermatološka lezija, dermatitis, psorijaza, kondilom, veruka, hemangiom, keloid, rak kože, atopički dermatitis, Behcetova bolest, kronična granulomatozna bolest, kutani T-stanični limfom, ulceracija, patološko stanje određeno s inicijalnom ozljedom koja je potakla upalu i disregulaciju imunološkog odgovora što vodi do kroničnog remodeliranja tkiva koje uključuje fibrozu i gubitak funkcije, renalnu ishemijsku ozljedu, cističnu fibrozu, sinusitis i rinitis ili ortopedsku bolest.
14. Farmaceutski oblik za primjenu egzosoma koji sadrži egzosom, u skladu s bilo kojim od zahtjeva 1-9, zajedno s dozatorom koji ima ulogu dostave egzosoma do mete.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6667108P | 2008-02-22 | 2008-02-22 | |
| EP09712571.0A EP2254586B1 (en) | 2008-02-22 | 2009-02-21 | Mesenchymal stem cell particles |
| PCT/SG2009/000062 WO2009105044A1 (en) | 2008-02-22 | 2009-02-21 | Mesenchymal stem cell particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150510T1 true HRP20150510T1 (hr) | 2015-06-05 |
Family
ID=40688500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150510TT HRP20150510T1 (hr) | 2008-02-22 | 2015-05-13 | Äśestice mezenhimskih matiäśnih stanica |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20110003008A1 (hr) |
| EP (1) | EP2254586B1 (hr) |
| JP (1) | JP5718648B2 (hr) |
| KR (1) | KR101640381B1 (hr) |
| CN (2) | CN102014934B (hr) |
| AU (1) | AU2009215934C1 (hr) |
| DK (1) | DK2254586T3 (hr) |
| ES (1) | ES2537516T3 (hr) |
| HR (1) | HRP20150510T1 (hr) |
| HU (1) | HUE026536T2 (hr) |
| PL (1) | PL2254586T3 (hr) |
| PT (1) | PT2254586E (hr) |
| SI (1) | SI2254586T1 (hr) |
| WO (1) | WO2009105044A1 (hr) |
Families Citing this family (162)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| GB0818725D0 (en) * | 2008-10-13 | 2008-11-19 | Habib Nagy A | Pharmaceutical composition |
| SG10201403202XA (en) * | 2009-07-23 | 2014-08-28 | Agency Science Tech & Res | Pre-natal mesenchymal stem cells |
| CN106619515A (zh) * | 2009-08-27 | 2017-05-10 | 工业研究与发展基金会有限公司 | 脂质体组合物及其用途 |
| CN102573856B (zh) * | 2009-09-10 | 2016-10-26 | 弗莱明·韦林 | 用于制备微小rna 的方法及其治疗性应用 |
| US20120263685A1 (en) * | 2009-10-08 | 2012-10-18 | Rnl Bio Co., Ltd | Anti-tumor composition comprising human-derived adult stem cells |
| EP2333047A1 (en) * | 2009-12-09 | 2011-06-15 | Fresenius Medical Care Deutschland GmbH | Adult stem cell derived conditioned medium and/or adult stem cells for use in the therapeutic treatment of a tumor disease |
| WO2011085276A2 (en) * | 2010-01-09 | 2011-07-14 | The Translational Genomics Research Institute | Methods and kits to predict prognostic and therapeutic outcome in small cell lung cancer |
| EP2363136A1 (en) * | 2010-03-02 | 2011-09-07 | Fresenius Medical Care Deutschland GmbH | Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease |
| US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
| CN101890050B (zh) * | 2010-07-14 | 2012-07-04 | 江苏大学 | 脐带间质干细胞来源膜性囊泡及其应用 |
| US20130209528A1 (en) * | 2010-10-18 | 2013-08-15 | Agency For Science, Technology And Research | Use of exosomes to promote or enhance hair growth |
| US20140004601A1 (en) * | 2010-12-20 | 2014-01-02 | Agency For Science, Technology And Research | Method of purifying exosomes |
| SG183579A1 (en) * | 2011-02-11 | 2012-09-27 | Agency Science Tech & Res | Methods of detecting therapeutic exosomes |
| CN103648509B (zh) * | 2011-03-11 | 2019-02-22 | 儿童医学中心公司 | 与间充质干细胞外来体相关的方法和组合物 |
| CN102225054B (zh) * | 2011-06-20 | 2013-01-16 | 河北科技大学 | 一种载有抗肿瘤药物微粒的制剂及其制备方法 |
| ITRM20110403A1 (it) | 2011-07-28 | 2013-01-29 | Ospedale Pediatrico Bambino Gesu | Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori. |
| WO2013025042A2 (ko) | 2011-08-16 | 2013-02-21 | 사회복지법인 삼성생명공익재단 | 줄기세포 유래 미세소포를 포함하는 신경 생성 촉진용 조성물 |
| US20140341882A1 (en) * | 2011-09-13 | 2014-11-20 | Takahiro Ochiya | Pharmaceutical product for preventing or treating alzheimer's disease |
| SG11201402649QA (en) | 2011-11-30 | 2014-06-27 | Agency Science Tech & Res | Gm1 ganglioside to annexin v microparticle polypeptide ratio for biological monitoring |
| WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
| ITRM20110685A1 (it) * | 2011-12-23 | 2013-06-24 | Internat Ct For Genetic En Gineering And | Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci |
| WO2013122950A1 (en) * | 2012-02-13 | 2013-08-22 | Wuyi Kong | Nprcps, pfdncs and uses thereof |
| US11286463B2 (en) | 2012-03-08 | 2022-03-29 | Advanced ReGen Medical Technologies, LLC | Reprogramming of aged adult stem cells |
| GB201302468D0 (en) | 2013-02-12 | 2013-03-27 | Reneuron Ltd | Stem cell product |
| US20150079046A1 (en) | 2012-04-03 | 2015-03-19 | Reneuron Limited | Stem cell microparticles |
| US20150297639A1 (en) * | 2012-04-18 | 2015-10-22 | Rhode Island Hospital, A Lifespan-Partner | Treating cancer |
| AU2013251442B2 (en) * | 2012-04-25 | 2017-07-06 | Genera Istrazivanja D.O.O. | Methods and compositions for treating and diagnosing acute myocardial infarction |
| SG11201407626QA (en) * | 2012-05-18 | 2014-12-30 | Agency Science Tech & Res | Umbilical cord mesenchymal stem cell exosomes |
| US9884076B2 (en) | 2012-06-05 | 2018-02-06 | Capricor, Inc. | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
| EP2687219A1 (en) | 2012-07-18 | 2014-01-22 | Universität Duisburg-Essen | Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions |
| KR20150059168A (ko) | 2012-07-19 | 2015-05-29 | 레뉴런 리미티드 | 줄기 세포 마이크로입자 |
| IN2015DN00934A (hr) | 2012-08-01 | 2015-06-12 | United Therapeutics Corp | |
| IN2015DN00976A (hr) | 2012-08-01 | 2015-06-12 | United Therapeutics Corp | |
| CA2881394C (en) | 2012-08-13 | 2024-05-14 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
| WO2014028763A1 (en) | 2012-08-15 | 2014-02-20 | The University Of Chicago | Exosome-based therapeutics against neurodegenerative disorders |
| US20190178879A1 (en) * | 2012-08-23 | 2019-06-13 | Stemcell Technologies Canada Inc. | Compositions and methods for rapid and reversible biomolecular labeling |
| CN103865873B (zh) * | 2012-12-12 | 2017-04-05 | 中国医学科学院基础医学研究所 | 亚全能干细胞分泌的外来体及其应用 |
| ES2697573T3 (es) * | 2013-01-09 | 2019-01-25 | United Therapeutics Corp | Tratamiento de la vasculopatía con prostaciclina y células madre mesenquimatosas |
| CN105163724A (zh) * | 2013-02-07 | 2015-12-16 | 葛兰素史密丝克莱恩生物有限公司 | 包含囊泡的药物组合物 |
| WO2014125277A1 (en) | 2013-02-12 | 2014-08-21 | Reneuron Limited | Method of producing microparticles |
| CA2900031A1 (en) * | 2013-02-14 | 2014-08-21 | Metanomics Health Gmbh | Means and methods for assessing the quality of a biological sample |
| JP6562897B2 (ja) | 2013-03-13 | 2019-08-21 | ユニバーシティー オブ マイアミＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉａｍｉ | 細胞培養上清および生体液からの微小胞の単離および精製のための方法 |
| US20140314872A1 (en) * | 2013-04-22 | 2014-10-23 | Hans Klingemann | Methods of Use of Culture Supernatant Obtained from Mesenchymal Stem Cells from Dogs and Cats for Treatment of Organ Dysfunction |
| CA2914615C (en) | 2013-06-05 | 2023-10-17 | Biotime, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
| WO2015001124A1 (en) | 2013-07-05 | 2015-01-08 | Université Catholique de Louvain | Conditioned medium from human adult liver stem cells and its use in the treatment of liver disorders |
| CN103409369A (zh) * | 2013-07-31 | 2013-11-27 | 江苏大学 | 一种快速建立间质干细胞衰老模型的方法 |
| US20160199413A1 (en) * | 2013-08-01 | 2016-07-14 | Isletone Ab | Mscs in the treatment of inflammatory pulmonary diseases |
| BR112016003053A2 (pt) * | 2013-08-14 | 2017-09-12 | Reneuron Ltd | micropartículas de células tronco e mirna |
| GB201317887D0 (en) | 2013-10-09 | 2013-11-20 | Reneuron Ltd | Product |
| SG11201601939VA (en) * | 2013-09-16 | 2016-04-28 | Agency Science Tech & Res | Method |
| GB201317889D0 (en) | 2013-10-09 | 2013-11-20 | Reneuron Ltd | Product and use |
| AU2014342477B2 (en) | 2013-11-01 | 2019-08-01 | Immunitybio, Inc. | Tumoricidal and antimicrobial compositions and methods |
| US9309314B2 (en) | 2013-12-03 | 2016-04-12 | Agency For Science, Technology And Research (A*Star) | Polypeptides, nucleic acids and uses thereof |
| US10772911B2 (en) | 2013-12-20 | 2020-09-15 | Advanced ReGen Medical Technologies, LLC | Cell free compositions for cellular restoration and methods of making and using same |
| JP6353073B2 (ja) | 2013-12-20 | 2018-07-04 | アドヴァンスド リジェン メディカル テクノロジーズ，エルエルシー | 細胞回復のための組成物並びにその作製及び使用方法 |
| US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
| TWI558421B (zh) * | 2014-03-06 | 2016-11-21 | 芯芮生技開發股份有限公司 | 幹細胞條件培養基用於製備抑制氧化作用達到皮膚抗老化之組成物的用途 |
| US9284528B2 (en) | 2014-04-18 | 2016-03-15 | Growgene Biotech Inc. | Use of stem cell conditioned medium to inhibit oxidation for anti-aging skin |
| US10568945B2 (en) | 2014-04-25 | 2020-02-25 | University Of Cincinnati | Compositions and methods for inducing liver regeneration by administering hepatocyte-derived exosomes |
| AU2015264519B2 (en) | 2014-05-18 | 2021-01-28 | Children's Medical Center Corporation | Methods and compositions relating to exosomes |
| US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
| CN107106614A (zh) * | 2014-09-15 | 2017-08-29 | 新加坡科技研究局 | 用外泌体治疗移植物抗宿主病（gvhd）或大疱性表皮松解症（eb）的方法 |
| CN108064265A (zh) * | 2014-09-29 | 2018-05-22 | 株式会社钟化 | 细胞培养基及使用其的培养方法 |
| WO2016054591A1 (en) | 2014-10-03 | 2016-04-07 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| KR101673059B1 (ko) * | 2014-11-26 | 2016-11-07 | 가톨릭관동대학교산학협력단 | 중간엽줄기세포 유래 미세소포체를 포함하는 발모촉진 또는 창상 치료용 약제학적 조성물 |
| RU2644650C2 (ru) | 2014-12-01 | 2018-02-13 | Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" | Материал стволовых клеток и способ его получения |
| KR101784050B1 (ko) * | 2014-12-23 | 2017-10-10 | 영남대학교 산학협력단 | 엑소솜을 유효성분으로 함유하는 피부 노화 예방 또는 치료용 약학조성물 |
| CN104673749B (zh) * | 2015-02-12 | 2017-10-20 | 江苏大学 | 一种粒细胞样髓源性抑制细胞来源exosomes及其应用 |
| WO2016149358A1 (en) * | 2015-03-16 | 2016-09-22 | Duncan Ross | Method of treatment comprising membrane-enclosed vesicle |
| GB201505747D0 (en) * | 2015-04-02 | 2015-05-20 | Univ Bristol | Exosomes |
| US20180116956A1 (en) * | 2015-04-02 | 2018-05-03 | Stegi-Ra Trust | Composition for use in treating celiac disease |
| US20160324898A1 (en) * | 2015-05-04 | 2016-11-10 | Stemedica International, Sa | Compositions and methods for the treatment of alzheimer's disease |
| US11291689B2 (en) | 2015-06-03 | 2022-04-05 | Aelan Cell Technologies, Inc. | Methods and devices for the production and delivery of beneficial factors from adipose-derived stem cells |
| EP3302541A4 (en) * | 2015-06-03 | 2018-12-05 | Aelan Cell Technologies Inc. | Methods and devices for the production and delivery of beneficial factors from stem cells |
| KR101751513B1 (ko) * | 2015-06-23 | 2017-06-27 | 한국과학기술연구원 | 인 비트로 섬유증 모델, 그의 제조방법 및 용도 |
| EP3328397B1 (en) * | 2015-07-31 | 2023-07-12 | Exotropin, LLC | Exosome compositions and methods for preparation and use thereof for regulating and conditioning skin and hair |
| US11357798B2 (en) | 2015-08-03 | 2022-06-14 | Osaka University | Mesenchymal stem cell-derived exosome |
| DE102015115158B4 (de) * | 2015-09-09 | 2017-07-13 | Fresenius Medical Care Deutschland Gmbh | Verfahren und Kit zur Diagnose von epithelial-mesenchymaler Transition (EMT) des Peritoneums |
| WO2017054086A1 (en) * | 2015-10-01 | 2017-04-06 | Exerkine Corporation | Treatment of genetic myopathies using bioengineered exosomes |
| US20170121685A1 (en) * | 2015-11-02 | 2017-05-04 | Tigenix S.A.U. | Mesenchymal stem cell-derived exosomes and their uses |
| US11857575B2 (en) | 2015-11-02 | 2024-01-02 | Takeda Pharmaceutical Company Limited | Mesenchymal stem cell-derived exosomes and their uses |
| EP3402543B1 (en) | 2016-01-11 | 2021-09-08 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
| CN108699519A (zh) * | 2016-01-12 | 2018-10-23 | 康干细胞生物技术有限公司 | 干细胞衍生的含有大量生长因子的外来体 |
| US10792477B2 (en) | 2016-02-08 | 2020-10-06 | Orbusneich Medical Pte. Ltd. | Drug eluting balloon |
| EP3868435A1 (en) | 2016-02-08 | 2021-08-25 | Orbusneich Medical Pte. Ltd | Drug eluting balloon |
| WO2017155894A1 (en) | 2016-03-07 | 2017-09-14 | Cfgenome, Llc | Noninvasive molecular controls |
| US11672830B2 (en) | 2016-04-15 | 2023-06-13 | Temple University-Of The Commonwealth System Of Higher Education | MicroRNA-294 and Lin28A as a driver of cardiac tissue proliferation in response to pathological injury |
| CA3023468A1 (en) | 2016-04-29 | 2017-11-02 | Advanced ReGen Medical Technologies, LLC | Microrna compositions and methods of making and using same |
| EA037967B1 (ru) * | 2016-05-06 | 2021-06-16 | Униците Эф Аг | ФАРМАЦЕВТИЧЕСКИЕ НОСИТЕЛИ, СОДЕРЖАЩИЕ микроРНК, ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ФИБРОЗНЫХ ЗАБОЛЕВАНИЙ, ВЫЗВАННЫХ ГИПЕРГЛИКЕМИЕЙ |
| CA3023349A1 (en) * | 2016-05-16 | 2017-11-23 | Exostem Biotec Ltd. | Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases |
| RU2708329C2 (ru) | 2016-05-31 | 2019-12-05 | Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" | Материал стволовых клеток, композиции и способы применения |
| US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
| TWI601741B (zh) * | 2016-07-11 | 2017-10-11 | 財團法人國家衛生研究院 | 利用前列腺素受體ｅｐ４－拮抗劑誘導幹細胞製造含有高囊泡含物之外泌體囊泡的方法及其應用 |
| JP7014449B2 (ja) | 2016-08-14 | 2022-02-01 | ラモット アット テル アビブ ユニバーシティ， リミテッド | 神経障害を処置するための間葉系細胞由来エキソソーム |
| US11541078B2 (en) | 2016-09-20 | 2023-01-03 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
| CN106265899A (zh) * | 2016-09-30 | 2017-01-04 | 广州赛莱拉干细胞科技股份有限公司 | 一种组合物及其在制备改善慢性鼻炎的产品中的应用 |
| EP3308795A1 (en) | 2016-10-12 | 2018-04-18 | Unicyte EV AG | A composition of extracellular vesicles (evs) and medical uses thereof |
| WO2018070939A1 (en) | 2016-10-12 | 2018-04-19 | Agency For Science, Technology And Research | Method for lyophilising an exosome |
| IL266175B2 (en) | 2016-10-24 | 2024-01-01 | United Therapeutics Corp | Enhancement of immunomodulatory properties of MSC using treprostinil |
| CN106636305A (zh) * | 2016-11-16 | 2017-05-10 | 宁夏医科大学总医院 | 一种检测人胎盘胎儿侧间充质干细胞抗氧化能力的方法 |
| WO2018109525A1 (en) * | 2016-12-14 | 2018-06-21 | Università Degli Studi Di Padova | New anti-angiogenic extracellurlar vesicles |
| WO2018186505A1 (ko) * | 2017-04-03 | 2018-10-11 | ㈜프로스테믹스 | 줄기세포 유래 엑소좀을 포함하는 상처 치료, 피부 개선 및 탈모 방지 또는 치료용 조성물 및 그 제조방법 |
| US11759482B2 (en) | 2017-04-19 | 2023-09-19 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
| AU2018266111A1 (en) * | 2017-05-08 | 2019-11-21 | Flagship Pioneering Innovations V, Inc. | Compositions for facilitating membrane fusion and uses thereof |
| EP3636271A4 (en) * | 2017-06-09 | 2021-03-03 | Osaka University | THERAPEUTIC FOR DILATED CARDIOMYOPATHY |
| KR102045188B1 (ko) * | 2017-06-30 | 2019-11-14 | 주식회사 엑소코바이오 | 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 피부염 개선 용도 |
| WO2019004738A2 (ko) * | 2017-06-30 | 2019-01-03 | 주식회사 엑소코바이오 | 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 피부염 개선 용도 |
| KR20190003316A (ko) | 2017-06-30 | 2019-01-09 | 주식회사 엑소코바이오 | 지방줄기세포 유래의 엑소좀 및/또는 세포외 소포체를 유효성분으로 포함하는 조성물의 피부염 개선 용도 |
| JP7037205B2 (ja) * | 2017-06-30 | 2022-03-16 | エクソコバイオ インコーポレイテッド | 幹細胞由来のエキソソームを有効成分として含む組成物のかゆみの抑制又は改善の用途 |
| CN111093681A (zh) * | 2017-07-16 | 2020-05-01 | 雷蒙特亚特特拉维夫大学有限公司 | 人类口腔粘膜干细胞分泌蛋白质组 |
| CN107189985B (zh) * | 2017-07-24 | 2021-02-02 | 中国人民解放军军事医学科学院基础医学研究所 | miRNA分子及其抑制剂在调控骨间充质干细胞成脂分化中的应用 |
| US20220023347A9 (en) * | 2017-08-15 | 2022-01-27 | Children's Medical Center Corporation | Purified mesenchymal stem cell exosomes and uses thereof |
| KR102197562B1 (ko) * | 2017-09-07 | 2020-12-31 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 포함하는 엑소좀 키트의 새로운 용도 |
| WO2019083201A2 (ko) * | 2017-10-24 | 2019-05-02 | 주식회사 엑소코바이오 | 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도 |
| WO2019088545A1 (ko) * | 2017-10-31 | 2019-05-09 | 주식회사 엑소코바이오 | 엑소좀 키트 및 이를 이용한 엑소좀의 경피 투과 증진 방법 |
| KR101964991B1 (ko) * | 2017-12-10 | 2019-04-02 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 포함하는 엑소좀 키트의 새로운 용도 |
| WO2019126068A1 (en) | 2017-12-20 | 2019-06-27 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
| KR102095628B1 (ko) | 2018-01-05 | 2020-04-01 | 재단법인 아산사회복지재단 | 유도만능 줄기세포 유래 중간엽 줄기세포 및 이로부터 유래된 엑소좀을 포함하는 피부질환의 개선, 예방 또는 치료용 조성물 |
| KR102096150B1 (ko) * | 2018-01-05 | 2020-04-02 | 재단법인 아산사회복지재단 | 인터페론 감마로 전처리된 유도만능 줄기세포 유래 중간엽 줄기세포 및 이로부터 유래된 엑소좀을 포함하는 피부질환의 개선, 예방 또는 치료용 조성물 |
| WO2019143847A1 (en) | 2018-01-18 | 2019-07-25 | Advanced ReGen Medical Technologies, LLC | Therapeutic compositions and methods of making and using the same |
| CN110141577A (zh) * | 2018-02-13 | 2019-08-20 | 上海三炬生物科技有限公司 | miRNA-24-3p核苷酸类似物在制备药物中的应用 |
| CN108414334A (zh) * | 2018-02-23 | 2018-08-17 | 中山大学附属第医院 | 一种从精液中分离提纯外泌体的方法 |
| KR20190104881A (ko) * | 2018-03-02 | 2019-09-11 | 주식회사 엑소코바이오 | 피부에 대한 레이저 빔 조사와 줄기세포 유래의 엑소좀 처리를 병용한 피부 미용방법 |
| KR20210005031A (ko) | 2018-03-29 | 2021-01-13 | 테크니온 리서치 엔드 디벨로프먼트 화운데이션 엘티디. | Pten 억제제를 포함하는 소포 및 이의 용도 |
| EP3773620A1 (en) * | 2018-04-10 | 2021-02-17 | Brainstorm Cell Therapeutics Ltd. | Cell-type specific exosomes and use thereof |
| RU2710368C2 (ru) * | 2018-05-29 | 2019-12-26 | Станислав Евгеньевич Волчков | Способ получения и концентрирования микроРНК-содержащих экзосом мультипотентных мезенхимально-стромальных клеток для применения в косметических и лекарственных средствах для стимуляции регенеративных процессов и замедления процессов старения |
| CN108865976B (zh) * | 2018-07-19 | 2022-06-28 | 复旦大学附属中山医院 | 一种离散汲取收集外泌体(exosome)的方法及试剂 |
| CN109125349A (zh) * | 2018-09-27 | 2019-01-04 | 天津欣普赛尔生物医药科技有限公司 | 一种具有外伤修复和抗衰老功能的凝胶的制备方法 |
| CN109543883A (zh) * | 2018-10-26 | 2019-03-29 | 上海城市交通设计院有限公司 | 一种基于多源数据融合的枢纽客流时空分布预测建模方法 |
| RS62863B1 (sr) * | 2018-11-16 | 2022-02-28 | Codiak Biosciences Inc | Konstruisane vanćelijske vezikule i njihove upotrebe |
| RU2720812C1 (ru) * | 2018-11-28 | 2020-05-13 | Общество с ограниченной ответственностью "НОВИСТЕМ" | Способ получения средства, обладающего противовоспалительной, регенеративной, иммуномодулирующей, детоксикационной, адаптогенной активностью и способного регулировать метаболизм |
| RU2720800C1 (ru) * | 2018-11-28 | 2020-05-13 | Общество с ограниченной ответственностью "НОВИСТЕМ" | Средство для крупного рогатого скота, обладающее противовоспалительной, регенеративной, иммуномодулирующей, детоксикационной, адаптогенной активностью и способное регулировать метаболизм |
| KR20210121183A (ko) * | 2019-01-30 | 2021-10-07 | 다이렉트 바이오로직스 엘엘씨 | 표적 특이적 엑소좀 및 성장 인자 제품을 개발하기 위한 방법 및 조성물 |
| WO2020172270A1 (en) * | 2019-02-19 | 2020-08-27 | Direct Biologics, Llc | Acellular intravenous infusion including mesenchymal stem cell growth factors and exosomes |
| US20220162561A1 (en) | 2019-04-04 | 2022-05-26 | Nissan Chemical Corporation | Composition for promoting secretion of extracellular vesicles |
| US10758571B1 (en) | 2019-04-09 | 2020-09-01 | Combangio, Inc. | Processes for making and using a mesenchymal stem cell derived secretome |
| WO2021009778A2 (en) * | 2019-07-18 | 2021-01-21 | Pandorum Technologies Private Limited | Methods for culturing mesenchymal stem cells, products thereof, and applications thereof |
| CN110447601A (zh) * | 2019-08-09 | 2019-11-15 | 南京医科大学 | 一种靶向巨噬细胞过表达基因小鼠模型的制备方法 |
| CN110693912A (zh) * | 2019-11-18 | 2020-01-17 | 深圳市人民医院 | 干细胞外泌体在制备促进创面愈合的产品中的应用 |
| WO2021146616A1 (en) * | 2020-01-17 | 2021-07-22 | Codiak Biosciences, Inc. | Cholesterol assays for quantifying extracellular vesicles |
| CN111494417B (zh) * | 2020-02-10 | 2024-04-09 | 寇晓星 | 诱导性细胞外囊泡在制备治疗肿瘤药物中的应用 |
| CN113274408A (zh) * | 2020-02-19 | 2021-08-20 | 中国医学科学院北京协和医院 | 一种磁性外泌体在制备创面修复或创面愈合产品中的应用 |
| WO2021181819A1 (ja) | 2020-03-13 | 2021-09-16 | 昭和電工マテリアルズ株式会社 | 細胞懸濁液の製造方法、及び、接着細胞の製造方法 |
| CN111500607B (zh) * | 2020-03-13 | 2022-05-03 | 首都医科大学附属北京口腔医院 | 种植体周围抗炎用融合基因、外泌体、生物涂料以及制备方法和应用 |
| EP4132479A1 (en) | 2020-04-07 | 2023-02-15 | Ramot at Tel-Aviv University Ltd. | Cannabidiol-containing compositions and uses thereof |
| KR102184428B1 (ko) * | 2020-05-25 | 2020-11-30 | 주식회사 씨케이엑소젠 | 중배엽줄기세포 유래의 엑소좀 생산방법 및 이로부터 제조된 배양액 |
| CN111690686B (zh) * | 2020-07-19 | 2021-01-15 | 广西康久生物科技有限公司 | 一种miRNA高表达在促进脐带间充质干细胞体外增殖和成骨分化方面的应用 |
| CN111888379A (zh) * | 2020-08-17 | 2020-11-06 | 济宁医学院附属医院 | 干细胞来源的微囊泡在制备修复瘢痕的制剂中的应用 |
| WO2022114724A1 (ko) * | 2020-11-27 | 2022-06-02 | (주)엑셀세라퓨틱스 | 고효율 및 고순도 엑소좀 생산용 배지 조성물 |
| WO2022126004A1 (en) * | 2020-12-11 | 2022-06-16 | Emory University | Hydrogels encapsulating enzymes that dephosphorylate adenosine and uses in medical applications |
| CN112941026B (zh) * | 2021-01-27 | 2023-03-31 | 上海交通大学 | 基于密度梯度离心提取细胞内体的方法 |
| US20220296645A1 (en) * | 2021-03-22 | 2022-09-22 | Spiritus Therapeutics, Inc. | Diagnostic and therapeutic uses of compositions comprising purified, enriched potent exosomes containing disease-based and therapy based signature cargo |
| CN113373112B (zh) * | 2021-06-30 | 2022-02-01 | 中国医学科学院阜外医院 | 基于通心络预处理的间充质干细胞来源外泌体及其制备方法 |
| CN114010756A (zh) * | 2021-10-25 | 2022-02-08 | 北京医院 | 一种卵巢再生贴片及其基于真空装置的制备方法 |
| WO2023123215A1 (zh) * | 2021-12-30 | 2023-07-06 | 医微细胞生物技术(广州)有限公司 | 细胞外囊泡的应用 |
| CN114848674A (zh) * | 2022-03-25 | 2022-08-05 | 四川大学华西医院 | 一种干细胞微粒在制备治疗帕金森的药物中的应用 |
| CN114703274B (zh) * | 2022-04-01 | 2023-08-15 | 中国人民解放军总医院 | Phpt1在预警和/或治疗高原病中的应用 |
| WO2023223312A1 (en) | 2022-05-15 | 2023-11-23 | Nurexone Biologic Ltd. | Anti-pten rna interference oligonucleotides and uses thereof |
| GB202215142D0 (en) * | 2022-10-13 | 2022-11-30 | Univ York | Novel cell lines and their use in therapy |
| GB202215141D0 (en) * | 2022-10-13 | 2022-11-30 | Univ York | Novel cell line and its use in therapy |
| CN115572709A (zh) * | 2022-10-18 | 2023-01-06 | 中晶生物技术股份有限公司 | 三维培养间充质干细胞微球在制备脱发修复与再生药物或制剂中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| DE4117305C2 (de) | 1991-05-27 | 1994-07-21 | Weidmueller Interface | Zange zum Ergreifen und/oder Verpressen von Bearbeitungsgegenständen |
| US5661034A (en) | 1991-07-18 | 1997-08-26 | Fuji Yakuhin Kogyo Kabushiki Kaisha | Serum-free medium for tissue culture containing tissue inhibitor of metalloproteinases and method for growing cells using the medium |
| AU5136093A (en) | 1992-09-25 | 1994-04-26 | Warner-Lambert Company | Peptide antagonists of sh2 binding and therapeutic uses thereof |
| EP0600832A1 (de) | 1992-11-27 | 1994-06-08 | Ciba-Geigy Ag | Diaminobenzoe- und Diaminophthalsäurederivate und ihre Verfahren als Proteinkinase-Inhibitoren |
| EP0600831A1 (de) | 1992-11-27 | 1994-06-08 | Ciba-Geigy Ag | Phthalazinonderivate |
| US5387584A (en) | 1993-04-07 | 1995-02-07 | Pfizer Inc. | Bicyclic ansamycins |
| US5631159A (en) | 1993-09-22 | 1997-05-20 | Creative Biomolecules, Inc. | Lipid-modified serum free media |
| US6139524A (en) | 1998-10-16 | 2000-10-31 | Scimed Life Systems, Inc. | Stent delivery system with perfusion |
| US7122019B1 (en) | 2000-11-28 | 2006-10-17 | Flowmedica Inc. | Intra-aortic renal drug delivery catheter |
| US7063679B2 (en) | 2002-09-20 | 2006-06-20 | Flowmedica, Inc. | Intra-aortic renal delivery catheter |
| AU2005262319A1 (en) * | 2004-07-01 | 2006-01-19 | Orthogen Ag | Immunosuppressive exosomes |
| USD544957S1 (en) | 2005-03-23 | 2007-06-19 | Rexam Dispensing Systems | Nasal spray dispenser |
| US20060286089A1 (en) * | 2005-04-08 | 2006-12-21 | Xcyte Therapies, Inc. | Compositions and methods for the treatment of burns and sepsis |
| KR20090043559A (ko) * | 2006-08-15 | 2009-05-06 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 중간엽 줄기세포 조절배지 |
| US20080256435A1 (en) * | 2007-01-26 | 2008-10-16 | Citation Technologies, Inc. | Interconnection of Document Preparation, Document Viewing, and Alert Processing in Structured Documents |
| KR20150059168A (ko) * | 2012-07-19 | 2015-05-29 | 레뉴런 리미티드 | 줄기 세포 마이크로입자 |
-
2009
- 2009-02-21 KR KR1020107019584A patent/KR101640381B1/ko active IP Right Grant
- 2009-02-21 WO PCT/SG2009/000062 patent/WO2009105044A1/en active Application Filing
- 2009-02-21 PT PT97125710T patent/PT2254586E/pt unknown
- 2009-02-21 JP JP2010547594A patent/JP5718648B2/ja not_active Expired - Fee Related
- 2009-02-21 DK DK09712571.0T patent/DK2254586T3/en active
- 2009-02-21 CN CN200980114014.3A patent/CN102014934B/zh not_active Expired - Fee Related
- 2009-02-21 HU HUE09712571A patent/HUE026536T2/en unknown
- 2009-02-21 AU AU2009215934A patent/AU2009215934C1/en not_active Ceased
- 2009-02-21 US US12/918,122 patent/US20110003008A1/en not_active Abandoned
- 2009-02-21 PL PL09712571T patent/PL2254586T3/pl unknown
- 2009-02-21 CN CN201410352490.1A patent/CN104127438B/zh not_active Expired - Fee Related
- 2009-02-21 EP EP09712571.0A patent/EP2254586B1/en active Active
- 2009-02-21 ES ES09712571.0T patent/ES2537516T3/es active Active
- 2009-02-21 SI SI200931203T patent/SI2254586T1/sl unknown
-
2014
- 2014-07-28 US US14/444,105 patent/US10780128B2/en active Active
-
2015
- 2015-05-13 HR HRP20150510TT patent/HRP20150510T1/hr unknown
-
2017
- 2017-01-12 US US15/404,774 patent/US20170189449A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL2254586T3 (pl) | 2015-09-30 |
| AU2009215934A1 (en) | 2009-08-27 |
| KR101640381B1 (ko) | 2016-07-18 |
| CN102014934B (zh) | 2014-08-20 |
| AU2009215934C1 (en) | 2014-05-08 |
| AU2009215934B2 (en) | 2013-10-24 |
| JP5718648B2 (ja) | 2015-05-13 |
| CN104127438A (zh) | 2014-11-05 |
| HUE026536T2 (en) | 2016-06-28 |
| US20170189449A1 (en) | 2017-07-06 |
| CN102014934A (zh) | 2011-04-13 |
| US20110003008A1 (en) | 2011-01-06 |
| EP2254586A1 (en) | 2010-12-01 |
| EP2254586B1 (en) | 2015-04-08 |
| WO2009105044A1 (en) | 2009-08-27 |
| JP2011513217A (ja) | 2011-04-28 |
| PT2254586E (pt) | 2015-05-18 |
| US20150190430A1 (en) | 2015-07-09 |
| US10780128B2 (en) | 2020-09-22 |
| DK2254586T3 (en) | 2015-06-15 |
| SI2254586T1 (sl) | 2015-07-31 |
| CN104127438B (zh) | 2021-01-08 |
| ES2537516T3 (es) | 2015-06-09 |
| KR20100122087A (ko) | 2010-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150510T1 (hr) | Äśestice mezenhimskih matiäśnih stanica | |
| Liu et al. | Exosomes from adipose-derived mesenchymal stem cells prevent cardiomyocyte apoptosis induced by oxidative stress | |
| Santos-Carballal et al. | Chitosan in non-viral gene delivery: Role of structure, characterization methods, and insights in cancer and rare diseases therapies | |
| Alyane et al. | Remote loading of doxorubicin into liposomes by transmembrane pH gradient to reduce toxicity toward H9c2 cells | |
| Boddapati et al. | Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo | |
| de Oliveira Junior et al. | Nasal administration of nanoencapsulated geraniol/ursodeoxycholic acid conjugate: Towards a new approach for the management of Parkinson's disease | |
| Tang et al. | Active targeting of the nucleus using nonpeptidic boronate tags | |
| Gan et al. | Nanoparticles containing constrained phospholipids deliver mRNA to liver immune cells in vivo without targeting ligands | |
| Fan et al. | Effect of different preparation methods on physicochemical properties of salidroside liposomes | |
| Gardikis et al. | New drug delivery nanosystem combining liposomal and dendrimeric technology (liposomal locked-in dendrimers) for cancer therapy | |
| Sancini et al. | Functionalization with TAT-peptide enhances blood-brain barrier crossing in vitro of nanoliposomes carrying a curcumin-derivative to bind amyloid-β peptide | |
| Visalli et al. | In vitro assessment of neurotoxicity and neuroinflammation of homemade MWCNTs | |
| An et al. | DNA exposure to buckminsterfullerene (C60): toward DNA stability, reactivity, and replication | |
| Li et al. | Preparation and quality evaluation of coenzyme Q10 long-circulating liposomes | |
| Hammel et al. | Correlating the structure and gene silencing activity of oligonucleotide-loaded lipid nanoparticles using small-angle X-ray scattering | |
| Grossi et al. | Development of blood-brain barrier permeable nanoparticles as potential carriers for salvianolic acid B to CNS | |
| Mehrotra et al. | Mitochondrial modulators improve lipid composition and attenuate memory deficits in experimental model of Huntington’s disease | |
| Dos Santos et al. | Changes in membrane biophysical properties induced by the Budesonide/Hydroxypropyl-β-cyclodextrin complex | |
| Xiao et al. | Soyasaponins inhibit the proliferation of Hela cells by inducing apoptosis | |
| Wang et al. | Novel nanoliposomal delivery system for polydatin: preparation, characterization, and in vivo evaluation | |
| Skarbek et al. | Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: synthesis and proof of concept | |
| Hu et al. | Ionic liquids revolutionizing biomedicine: recent advances and emerging opportunities | |
| Luo et al. | Advances in oral mesenchymal stem cell-derived extracellular vesicles in health and disease | |
| Li et al. | Supramolecular integration of multifunctional nanomaterial by mannose-decorated azocalixarene with ginsenoside Rb1 for synergistic therapy of rheumatoid arthritis | |
| Refai et al. | Enhanced wound healing potential of spirulina platensis nanophytosomes: Metabolomic profiling, molecular networking, and modulation of HMGB-1 in an excisional wound rat model |